Emerging cancer models for drugs and novel dosages development WCRJ 2022; 9: e2153 DOI: 10.32113/wcrj_20221_2153
Evaluation of clinical and economic impact of pharmacogenomics testing in taxanes-based therapy WCRJ 2016; 3 (3): e744
A cost-effectiveness method for the enrichments of minority mutant DNA in a large excess of wild type DNA. Detection of B-RAF 1799T>A (V600E) mutations in the thyroid fine needle aspirate WCRJ 2014; 1 (4): e399